Nothing unsubstantiated about Biotron's HIV results to date. They are what they are, and quite good too.
Will this lead to further progress? Possibly, based on the evidence and the reasoning:
- A new immunlogical response from BIT225 has occured
- HIV treatment requires a new immonological response to proceed
- Therefore BIT225 will proceed
Now, in the world of spec trading, little is substantiated of the future.
So if you are looking for substantiation now, I suggest you leave the spec end of the market.
Ann: Letter to Shareholders, page-124
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
